International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• The International Prognostic Index (IPI) is standard for diffuse large B-cell lymphoma (DLBCL) prognosis.
• Novel biomarkers are needed for targeted therapies like immune checkpoint blockade (ICB).

Purpose of the Study:

• To develop a novel immune prognostic model for DLBCL.
• To assess the model's ability to predict survival and response to ICB.

Main Methods:

• Utilized The Cancer Genome Atlas and Gene Expression Omnibus datasets for DLBCL gene expression and clinical data.
• Applied weighted gene co-expression network analysis to identify immune-related genes.
• Constructed an IPI-based immune prognostic model (IPI-IPM) using eight selected genes.

Main Results:

• The IPI-IPM, based on CMBL, TLCD3B, SYNDIG1, ESM1, EPHA3, HUNK, PTX3, and IL12A, showed high-risk patients had worse survival.
• High IPI-IPM scores correlated with immune pathways, mutations (KMT2D, CD79B), and immune checkpoints (PD-L1, BTLA, SIGLEC7).
• These factors suggest a greater potential response to ICB therapy in high-risk IPI-IPM subgroups.

Conclusions:

• The IPI-IPM demonstrates independent prognostic value in DLBCL.
• It provides an immunological perspective on DLBCL progression.
• The model aids in developing immunotherapy strategies for DLBCL.